Using physiologically relevant preclinical models, including patient-derived xenografts and ex vivo explant models, we showed that CB inhibited TNBC, ER+, and ER mutant breast cancer growth and metastasis without targeting normal mammary tissue. This evidence concerns the gene ESR1 and breast carcinoma.